Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as GBX 34 and last traded at GBX 34.55, with a volume of 121483 shares traded. The stock had previously closed at GBX 35.
Faron Pharmaceuticals Oy Trading Down 1.3%
The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 155.01. The company’s fifty day moving average price is GBX 40.59 and its two-hundred day moving average price is GBX 43.80. The firm has a market cap of £70.10 million, a PE ratio of -3.00 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
- AI Is Making Cybersecurity Harder to Ignore—These 3 ETFs Offer a Broad Bet
- Campbell’s Dividend Cut May Reset the Stock, But the Turnaround Still Has to Deliver
- Copper Is the AI Trade No One Priced In—3 Miners With the Most to Gain
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
